SCHEMBL27185316

SCHEMBL27185316

CNc1ccc2c(OC)cc(C(=O)O)cc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.48
HCAR3 P49019 1/20 0.46
ACACA Q13085 1/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA6 P23280 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA3 P07451 1/20 0.46
PKM P14618 1/20 0.46
CA5A P35218 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
TPMT P51580 2/20 0.45
PTGS2 P35354 1/20 0.44
CSNK2A1 P68400 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27185229 0.89 ACACA (0.46) ALOX15ACACAPDE3BCSNK2A1NPC1
SCHEMBL27185312 0.81 HCAR3 (0.50) HCAR3CSNK2A1CSNK2A2CSNK2BNPC1
SCHEMBL21723280 0.75 CA12 (0.58) ALOX15CA12CA1CA2CA4
SCHEMBL21729812 0.73 CA12 (0.56) ALOX15CA12CA1CA2CA4
SCHEMBL2671414 0.73 HCAR3 (0.56) HCAR3ACACAHTTNPC1RAB9A
SCHEMBL27060737 0.73 NCF1 (0.65) ALOX15PDE3BPDE3ASLC2A1NCF1
SCHEMBL27185326 0.72 KDM4E (0.60) ALOX15CA12CA1CA2CA7
SCHEMBL25981084 0.72 SMN1; SMN2 (0.67) ALOX15CSNK2A1CSNK2A2CSNK2BHTT
SCHEMBL28857298 0.72 CA1 (0.69) CA12CA1CA2CA4CA6
SCHEMBL20392776 0.70 CA12 (0.56) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562017-A1 NOVEL ACC INHIBITORS Pfizer Inc. (US) 2025-06-04 EP disclosed
CN-120019059-A Novel ACC inhibitors 辉瑞公司 2025-05-16 CN disclosed
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
WO-2024023727-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB ALOX15 1092/4885HCAR3 32/4885ACACA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.